Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
Retrieved on:
Tuesday, May 26, 2020
Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") announced today it has executed a new Equity Line Purchase Agreement with Cavalry Fund I, LP (Cavalry) to sell up to $10 Million in common stock to Cavalry over a term of 24 months.
Key Points:
- Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") announced today it has executed a new Equity Line Purchase Agreement with Cavalry Fund I, LP (Cavalry) to sell up to $10 Million in common stock to Cavalry over a term of 24 months.
- Alan Collier, Endonovo CEO comments, We are excited to establish this relationship p with Cavalry and the flexibility to potentially access capital on a cost-effective basis.
- By focusing on lowering costs to obtain working capital, we believe this agreement allows Endonovo to receive funding to meet our projected sales growth on favorable terms.
- Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticalstherapeutic devices.